N4 PHARMA PLC

Report Publication Announcement • Oct 2, 2023

National Storage Mechanism | Additional information

RNS Number : 2596O

N4 Pharma PLC

02 October 2023

Reach - Non-Regulatory

2 October 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

Investor Presentation

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that an updated investor presentation ("Presentation") incorporating the Company's acquisition of a 71% interest in Nanogencis Limited is now available on the N4 Pharma website.  To view a copy of the Presentation, please click here: http://www.rns-pdf.londonstockexchange.com/rns/2596O_1-2023-10-1.pdf

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director	Via IFC Advisory
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking)	Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker IFC Advisory Limited Financial PR Graham Herring Zach Cohen	Tel: +44 (0)20 3657 0050 Tel: +44 (0)20 3934 6630

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFIFSDITLLIIV